FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations